Zoe A. Stewart, MD, PhD
Assistant Professor
Department of Surgery
Division of Transplant and Hepatobiliary Surgery
zoe-stewart@uiowa.edu
Office Telephone: 319-356-1334
Transplant and Hepatobiliary Surgery Clinic
Telephone: 319-356-2902
Medical School:
- Vanderbilt School of Medicine, Nashville, TN
Residency:
- Johns Hopkins Hospital, Baltimore, MD
Fellowship:
- Abdominal Transplant Surgery, Johns Hopkins Hospital, Baltimore, MD
Certification:
- American Board of Surgery
Honors and Achievements:
- 2007 John L. Cameron Award for Technical Excellence – Johns Hopkins
- 2002 H. William Scott, Jr. Prize in Surgery - Vanderbilt
- 2002 John G. Coniglio Prize in Biochemistry - Vanderbilt
- 1999 Susan G. Komen Breast Cancer Foundation Pre-doctoral Grant
- 1999 Leon Cunningham Graduate Biochemistry Award - Vanderbilt
- 1995 Phi Kappa Phi National Graduate Scholarship
- 1995 University of Tulsa Outstanding Honors Thesis Award
- 1995 University of Tulsa Faculty Honor Medal - College of Arts & Sciences
Societies and Organizations:
- American Society of Transplant Surgeons
- American Society of Transplantation
- International Society of Liver Transplantation
- American College of Surgeons
Research Interests:
- Epidemiologic studies using UNOS national registry:
- ABO incompatible liver transplant analysis
- Liver/pancreas/kidney graft survival after preservation with HTK versus UW
- Hepatic artery thrombosis analysis/risk stratification
Recent Publications:
- Stewart Z.A., Koslowski T., Segev D., and Klein A.S. (2006) Successful transplantation of cadaveric polycystic liver: case report and review of the use of polycystic livers for liver transplantation. Transplantation. 81(2): 284-6.
- Stewart Z.A., Cameron A.M., Singer A.L., Dagher, N.N., Montgomery R.A., Segev D.L. (2009) Histidine-Tryptophan-Ketoglutarate (HTK) is associated with reduced graft survival in pancreas transplantation. Am J Transplant. 9(1): 217-21.
- Stewart Z.A., Cameron A.M., Singer A.L., Montgomery R.A., Segev D.L. (2009) Histidine-Tryptophan-Ketoglutarate (HTK) is associated with reduced graft survival in deceased donor livers, especially those donated after cardiac death. Am J Transplant. 9(2): 286-93.
- Stewart Z.A., Lonze B.E., Warren D.S., Dagher N.N., Singer A.L., Montgomery R.A., Segev D.L. (2009) Histidine-Tryptophan-Ketoglutarate (HTK) is associated with reduced graft survival of deceased donor kidney transplants. Am J Transplant. 9(5): 1048-54.
- Stewart Z.A., Locke J.E., Montgomery R.A., Singer A.L., Cameron A.M., Segev D.L. (2009) ABO-incompatible deceased donor liver transplantation in the United States: a national registry analysis. Liver Transplantation. 15(8):883-93.